Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies

Scandinavian Journal of Gastroenterology

Volumn 53, Issue 4, 2018, Pages 379-389

  Ahluwalia, Bani ^a,b   Moraes, Luiza ^a   Magnusson, Maria K ^a   Öhman, Lena ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Calmino Group AB   (Sweden)

Author keywords

biological therapies; chronic inflammation; Crohn s disease; dysbiosis; dysregulated immune response; IBD; immunopathogenesis; ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; COBITOLIMOD; CYTOKINE; FILGOTINIB; FONTOLIZUMAB; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 9; MONGERSEN; OZANIMOD; RISANKIZUMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; TOLL LIKE RECEPTOR; TRALOKINUMAB; USTEKINUMAB; VEDOLIZUMAB;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; B LYMPHOCYTE; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LYMPHOCYTE HOMING; LYMPHOID CELL; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TH9 CELL; BIOLOGICAL THERAPY; CROHN DISEASE; IMMUNOLOGY; ULCERATIVE COLITIS;

BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; INFLAMMATORY BOWEL DISEASES;

EID: 85045850918     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2018.1447597     Document Type: Review

References (147)

1. Ahluwalia B, Magnusson MK, Ohman L., Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scand J Gastroenterol. 2017;52:1185–1193.
2. Wallace KL, Zheng LB, Kanazawa Y, et al. Immunopathology of inflammatory bowel disease. WJG. 2014;20:6–21.
3. Xavier RJ, Podolsky DK., Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434.
4. de Souza HS, Fiocchi C., Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
5. Xu XR, Liu CQ, Feng BS, et al. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20:3255–3264.
6. Round JL, Mazmanian SK., The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313–323.
7. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
8. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54.
9. Moss AC., Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3:63–68.
10. Peterson LW, Artis D., Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14:141–153.
11. Kaistha A, Levine J., Inflammatory bowel disease: the classic gastrointestinal autoimmune disease. Curr Probl Pediatr Adolesc Health Care. 2014;44:328–334.
12. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 2014;13:3–10.
13. Salim SY, Soderholm JD., Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362–381.
14. Michielan A, D’Inca R., Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:628157.
15. Anderson CA, Boucher G, Lees CW., Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246–252.
16. UK IBD Genetics Consortium, Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009;41:1330–1334.
17. Gassler N, Rohr C, Schneider A, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol. 2001;281:G216–G228.
18. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215–223.
19. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut. 2007;56:61–72.
20. Weber CR, Nalle SC, Tretiakova M, et al. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008;88:1110–1120.
21. Klag T, Stange EF, Wehkamp J., Defective antibacterial barrier in inflammatory bowel disease. Dig Dis. 2013;31:310–316.
22. Atreya R, Neurath MF., Factors affecting mucosal homeostasis: a fine balance. In: Targan SR, Shanahan F, Karp LC, editors. Inflammatory bowel disease: translating basic science into clinical practice. Chichester: Wiley-Blackwell; 2010. p. 52–60.
23. Rimoldi M, Chieppa M, Salucci V, et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol. 2005;6:507–514.
24. Iliev ID, Spadoni I, Mileti E, et al. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut. 2009;58:1481–1489.
25. Magnusson MK, Brynjolfsson SF, Dige A, et al. Macrophage and dendritic cell subsets in IBD: ALDH + cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation. Mucosal Immunol. 2016;9:171–182.
26. Saruta M, Targan SR, Mei L, et al. High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females. Inflamm Bowel Dis. 2009;15:321–327.
27. Torok HP, Glas J, Tonenchi L, et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004;127:365–366.
28. Henckaerts L, Vermeire S., NOD2/CARD15 disease associations other than Crohn's disease. Inflamm Bowel Dis. 2007;13:235–241.
29. Noguchi E, Homma Y, Kang X, et al. A Crohn’s disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009;10:471–479.
30. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129:50–65.
31. Middel P, Raddatz D, Gunawan B, et al. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut. 2006;55:220–227.
32. Neurath MF., Cytokines in inflammatory Bowel disease. Nat Rev Immunol. 2014;14:329–342.
33. Kuznetsov NV, Zargari A, Gielen AW, et al. Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol. 2014;14:79.
34. Pedersen G, Andresen L, Matthiessen MW, et al. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol. 2005;141:298–306.
35. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005;115:695–702.
36. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088–1094.
37. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50:206–211.
38. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut. 2004;53:70–77.
39. Levin AD, Wildenberg ME, van den Brink GR., Mechanism of action of anti-TNF therapy in inflammatory Bowel disease. ECCOJC. 2016;10:989–997.
40. Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63:1255–1264.
41. Rose-John S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8:1237–1247.
42. Kimura A, Kishimoto T., IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830–1835.
43. Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988;141:1543–1549.
44. Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut 2017 [cited 2017 Dec 15]. DOI: 10.1136/gutjnl-2017-314562.
45. Bruck N, Suttorp M, Kabus M, et al. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with Anakinra and corticosteroids. J Clin Rheumatol. 2011;17:23–27.
46. Mertens M, Singh JA., Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118–1125.
47. Geremia A, Arancibia-Carcamo CV., Innate lymphoid cells in intestinal inflammation. Front Immunol. 2017;8:1296.
48. Goldberg R, Prescott N, Lord GM, et al. The unusual suspects–innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:271–283.
49. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–149.
50. Ebbo M, Crinier A, Vely F, et al. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17:665–678.
51. Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208:1127–1133.
52. Bernink JH, Peters CP, Munneke M, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14:221–229.
53. Buonocore S, Ahern PP, Uhlig HH, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature. 2010;464:1371–1375.
54. Zhou L, Chong MM, Littman DR., Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009;30:646–655.
55. Shuai K, Liu B., Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3:900–911.
56. Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462:1–13.
57. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223:132–142.
58. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2924–2937.
59. Sandborn WJ, Su C, Panes J., Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377:496–497.
60. Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–275.
61. Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049–1059.
62. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–4243.
63. Romagnani S., Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285–294.
64. Zhu J, Yamane H, Paul WE., Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445–489.
65. Galvez J., Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014;2014:928461.
66. Zundler S, Neurath MF., Immunopathogenesis of inflammatory Bowel diseases: functional role of T cells and T cell homing. Clin Exp Rheumatol. 2015;33:S19–S28.
67. Huang Y, Chen Z., Inflammatory bowel disease related innate immunity and adaptive immunity. Am J Transl Res. 2016;8:2490–2497.
68. Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78:127–131.
69. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112:1169–1178.
70. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–1270.
71. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564.
72. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490–1497.
73. Fuss IJ, Strober W., The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol. 2008;1(Suppl 1):S31–S33.
74. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology. 2005;128:687–694.
75. Miossec P, Kolls JK., Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763–776.
76. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233–242.
77. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut. 2006;55:1131–1137.
78. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967–974.
79. Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity. 2009;30:92–107.
80. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629–1636.
81. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423–7430.
82. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70.
83. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463.
84. Thompson AI, Lees CW., Genetics of ulcerative colitis. Inflamm Bowel Dis. 2011;17:831–848.
85. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12:9–15.
86. Sandborn WJ, Feagan BG, Fedorak RN, Ustekinumab Crohn’s Disease Study Group, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–1141.
87. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519–1528.
88. Feagan BG, Sandborn WJ, Gasink C, Group U-I-US, et al. Ustekinumab as induction and maintenance therapy for Crohn’s Disease. N Engl J Med. 2016;375:1946–1960.
89. Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's Disease: a phase 2a study. Gastroenterology. 2017;153:77–86. e6.
90. Hueber W, Sands BE, Lewitzky S, Secukinumab in Crohn’s Disease Study G, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700.
91. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271–2279.
92. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14:282–289.
93. Nalleweg N, Chiriac MT, Podstawa E, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015;64:743–755.
94. Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9:1341–1346.
95. Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676–686.
96. Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 2010;33:192–202.
97. Weigmann B, Neurath MF., Th9 cells in inflammatory bowel diseases. Semin Immunopathol. 2017;39:89–95.
98. O'Garra A, Vieira P., Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801–805.
99. Yamada A, Arakaki R, Saito M, et al. Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2016;22:2195–2205.
100. Schmidt A, Oberle N, Krammer PH., Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51.
101. Mittal SK, Cho KJ, Ishido S, et al. Interleukin 10 (IL-10)-mediated immunosuppression: March-I induction regulates antigen presentation by macrophages but not dendritic cells. J Biol Chem. 2015;290:27158–27167.
102. Park JH, Peyrin-Biroulet L, Eisenhut M, et al. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16:416–426.
103. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601–609.
104. Maynard CL, Weaver CT., Intestinal effector T cells in health and disease. Immunity. 2009;31:389–400.
105. Zenewicz LA, Antov A, Flavell RA., CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009;15:199–207.
106. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868–1878.
107. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010;30:80–89.
108. Fantini MC, Rizzo A, Fina D, et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology. 2009;136:1308–1316.
109. Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012;36:850–857.
110. Schottelius AJ, Mayo MW, Sartor RB, et al. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem. 1999;274:31868–31874.
111. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143:347–355.
112. Moran CJ, Walters TD, Guo CH, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013;19:115–123.
113. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev. 2003;55:241–269.
114. Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology. 2012;143:1207–1217.
115. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996;38:365–375.
116. Hevia A, Lopez P, Suarez A, et al. Association of levels of antibodies from patients with inflammatory bowel disease with extracellular proteins of food and probiotic bacteria. Biomed Res Int. 2014;2014:351204.
117. Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365–1368.
118. El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008;57:714.
119. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243–e246.
120. Pichler WJ., Adverse side-effects to biological agents. Allergy. 2006;61:912–920.
121. Anderson PJ., Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum. 2005;34:19–22.
122. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435.
123. Fischer A, Zundler S, Atreya R, et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016;65:1642–1664.
124. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005;202:1063–1073.
125. Adams DH, Eksteen B., Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6:244–251.
126. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74:185–195.
127. Miyasaka M, Tanaka T., Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol. 2004;4:360–370.
128. Ley K, Rivera-Nieves J, Sandborn WJ, et al. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016;15:173–183.
129. Vermeire S, Loftus EV, Jr, Colombel JF, et al. Long-term efficacy of vedolizumab for Crohn's disease. J Crohns Colitis. 2017;11:412–424.
130. Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722–729.
131. Wang MC, Zhang LY, Han W, et al. PRISMA–efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93:e326.
132. Fuchs F, Schillinger D, Atreya R, et al. Clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles. Front Immunol. 2017;8:764.
133. Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:135–144.
134. Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754–1762.
135. Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. Br J Pharmacol. 2016;173:1778–1792.
136. Marsolais D, Rosen H., Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov. 2009;8:297–307.
137. D'Haens GR, Sartor RB, Silverberg MS, et al. Future directions in inflammatory bowel disease management. J Crohns Colitis. 2014;8:726–734.
138. Hanauer SB., Combination therapy for inflammatory bowel disease. Gastroenterol Hepatol (NY). 2017;13:296–298.
139. Sandborn WJ. The present and future of inflammatory bowel disease treatment. Gastroenterol Hepatol (NY). 2016;12:438–441.
140. Withers DR, Hepworth MR, Wang X, et al. Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med. 2016;22:319–323.
141. Popp V, Gerlach K, Mott S, et al. Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 and reduces colitis in mice. Gastroenterology. 2017;152:176–192. e5.
142. Allez M, Skolnick BE, Wisniewska-Jarosinska M, et al. Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn's disease: a randomised controlled trial. Gut. 2017;66:1918–1925.
143. Danese S, Vuitton L, Peyrin-Biroulet L., Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545.
144. Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
145. Stallmach A, Hagel S, Bruns T., Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167–182.
146. Magnusson MK, Strid H, Sapnara M, et al. Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. ECCOJC. 2016;10:943–952.
147. West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579–589.